Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 6, 2020

View Archived Issues

Targeted delivery improves checkpoint blockade

A potent and selective allosteric inhibitor of SHP2 that overcomes tumor resistance to osimertinib

Carcinogens need not be mutagens

Lantern Pharma and Georgetown University advance development of LP-184

New JAK inhibitors identified at Beijing Scitech-Mq Pharmaceuticals

Patient screening ongoing in phase IIa study of IP-2018

NervGen provides updates regarding development of NVG-291

First-in-human data for the anti-BCMA antibody-drug conjugate AMG-224

Hangzhou Innogate Pharma discovers ALK/mutant EGFR/MAP4K1 inhibitors

Kyushu University presents new lysosomal alpha-glucosidase inhibitors

Central China Normal University synthesizes new TRK inhibitors

Three win Nobel Prize for hepatitis C discoveries

NuvoBio patents N-lysine methyltransferase KMT5A inhibitors

Pralsetinib shows promising activity in RET-mutant MTC in the phase I/II ARROW trial

PALLAS: palbociclib not beneficial in early breast cancer treated with endocrine therapy

miRagen to discontinue internal development of cobomarsen for CTCL

NMD Pharma begins phase I/IIa trial of NMD-670 to treat symptoms of myasthenia gravis

Santhera ends development of idebenone following phase III futility analysis

Phase I data for LXH-254 plus LTT-462 in patients with KRAS- or BRAF-mutant NSCLC

Clinical results reported for anti-TIGIT antibody vibostolimab +/- pembrolizumab in NSCLC

FDA approves Opdivo + Yervoy for unresectable malignant pleural mesothelioma

Promising data seen in phase I studies of bispecific HER2/4-1BB molecule PRS-343

Tarsius reports phase I/II data on TRS-01 in active noninfectious anterior uveitis

Kodiak Sciences begins pivotal studies of KSI-301 in DME and RVO

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...